parkinson's disease retatrutide clinical trial A Big Week for GLP-1 Drugs - by Eric Topol Retatrutide Achieves Up to 30.3%

Cancer Epidemiol Biomark Prev

Tirzepatide reduced the apnea-hypopnea index by about 25 to 29 events per hour from baselines of roughly 50 events per hour, a reduction of about half, alongside substantial weight loss

Continued Growth in GLP-1 Compounding Despite Regulatory Headwinds Despite the resolution of GLP-1 shortages and increased regulatory scrutiny, compounded prescriptions for semaglutide and tirzepatide continue to rise

Cureus provides an equitable, efficient publishing and peer reviewing experience without sacrificing publication times

GLP-1 receptor agonists mimic this hormone, leading to: Reduced hunger and cravings Improved insulin sensitivity Slower gastric emptying (helping you feel full longer) Fat loss without extreme caloric restriction Can GLP-1 Cause Muscle Loss